ClinicalTrials.gg
RecruitingNCT04900818Updated Mar 5, 2026

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of TJ033721 (givastomig) and TJ033721 (givastomig) , nivolumab, chemotherapy in Solid Tumor, Advanced Cancer and Metastatic Cancer, sponsored by I-Mab Biopharma US Limited. Recruiting at 21 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by I-Mab Biopharma US Limited · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2021; still recruiting 5 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
330
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,054 studies in Neoplasm Metastasis with a site in United States — 346 open to participants now, 542 under way, 58 of them phase 3. Neoplasm Metastasis · United States.

Planned enrollment
195th of 1,863
330 · median 43
Started
2021
with 133 others
Phase 1
709 of 2,054
128 open now
Primary completion
2026-12
later than 129 of 540 live
Registered
1,547th of 2,054
by date

Among the 2,054 studies in Neoplasm Metastasis with a site in United States, this one is the 195th largest by planned enrollment of the 1,863 interventional ones that give a count, is one of 134 that started in 2021, is one of 709 in phase 1, reaches primary completion later than 129 of the 540 other live ones, and was the 1,547th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

346 of the 2,054 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,054 studies in Neoplasm Metastasis with a site in United States, or all of them as a file.
02

Study summary

This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors.

03

Conditions studied

  • Solid Tumor
  • Advanced Cancer
  • Metastatic Cancer
  • Gastric Cancer
  • Gastroesophageal Junction Carcinoma
  • Esophageal Adenocarcinoma
  • PDAC - Pancreatic Ductal Adenocarcinoma
  • Biliary Tract Cancer (BTC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part 1 - Monotherapy Subjects with advanced or solid tumor in subjects whose disease has progressed despite standard therapy, or who has no further standard therapy, or who is unsuitable for available standard treatment options.

Part 2 - Combination Therapy Subjects with treatment naïve locally advanced, unresectable or metastatic gastric, GEJ, esophageal adenocarcinoma;

Part 3: Combination Therapy Subjects with unresectable, locally advanced or metastatic confirmed pancreatic adenocarcinoma;

Part 4: Combination Therapy Subjects with unresectable, locally advanced or metastatic histologically confirmed biliary tract cancer.

  • (ECOG) performance status 0 or 1 with adequate organ function
  • Have known status with prior testing by immunohistochemistry and a corresponding combined positive score (CPS)

For dose expansion and Part 2, Part 3, Part 4 Combination subjects:

  • Must have CLDN18.2-positive tumor expression

Exclusion criteria

Exclusion Criteria

  • Prior exposure to CLDN18.2 -targeted therapy
  • Prior exposure to 4-1BB agonists
  • Second within the last 3 years with the exception of cutaneous squamous cell carcinoma or cutaneous basal cell carcinoma or cervical carcinoma in situ
  • Known active or chronic or , other hepatitides
  • Unstable/active ulcer or digestive tract bleeding within 6 weeks
  • Active disease requiring systemic treatment within the past 2 years
  • Active interstitial lung disease (ILD) or pneumonitis or a history of ILD or pneumonitis requiring treatment
  • Known active and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are clinically stable and without requirement of treatment for at least 14 days prior to first dose of study treatment;
  • (NYHA) Class 3 or 4 congestive heart failure, severe/unstable angina, myocardial infarction (MI), symptomatic congestive heart failure, cerebrovascular accident, (TIA), arterial embolism, percutaneous transluminal coronary angioplasty (PTCA), or coronary artery bypass grafting (CABG) in the previous 6 months
  • Diagnosis of immunodeficiency such as known active
  • Any active infection requiring parenteral treatment

For Part 2, 3, 4 Combination subjects:

  • Prior treatment with or PD-L1 agent
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Care provider)
Enrollment
330 participants (estimated)

Study arms

  • Experimental
    TJ033721 (givastomig)

    Dose Escalation: TJ033721 will be administered at up to 8 dose levels (0.1, 0.3, 1, 3, 5, 8, 12 and 15 mg/kg) bi weekly (Q2W) and 1 dose level (18 mg/kg) every 3 weeks (Q3W) During dose expansion, TJ033721 will be administered Q2W, starting at the RP2D or MTD in dose escalation.

    Drug: TJ033721 (givastomig)

  • Experimental
    TJ033721 (givastomig) in combination with nivolumab and chemotherapy

    TJ033721 will be administered in combination with nivolumab and chemotherapy

    Drug: TJ033721 (givastomig) , nivolumab, chemotherapy

  • Experimental
    TJ033721 (givastomig) in combination chemotherapy

    TJ033721 (givastomig) will be administered in combination chemotherapy

    Drug: TJ033721 (givastomig), chemotherapy

  • Experimental
    TJ033721 (givastomig) in combination with durvalumab and chemotherapy

    TJ033721 (givastomig) will be administered in combination with durvalumab and chemotherapy

    Drug: TJ033721 (givastomig), durvalumab, chemotherapy

Interventions

  • DrugTJ033721 (givastomig)

    Tetravalent IgG(H)-scFv fusion-type of bi-specific antibody (BsAb)

  • DrugTJ033721 (givastomig) , nivolumab, chemotherapy

    Tetravalent IgG(H)-scFv fusion-type of bi-specific antibody (BsAb), nivolumab, chemotherapy

  • DrugTJ033721 (givastomig), chemotherapy

    Tetravalent IgG(H)-scFv fusion-type of bi-specific antibody (BsAb), chemotherapy

  • DrugTJ033721 (givastomig), durvalumab, chemotherapy

    Tetravalent IgG(H)-scFv fusion-type of bi-specific antibody (BsAb), durvalumab, chemotherapy

This study also gives Nivolumab, Durvalumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicities (DLTs)

    Time frame: 28 days

  2. Incidence and severity of AEs

    The CTCAE criteria will be used to assess adverse events on this trial.

    Time frame: Up to 100 days post last dose

  3. Maximum tolerated or administered dose (MTD, MAD)

    Based on DLT definitions

    Time frame: 28 Days

Secondary outcomes

  1. Pharmacokinetic (PK) Parameters: AUC∞

    Area under the curve from time zero extrapolated to infinity (AUC∞)

    Time frame: Up to 100 days post last dose

  2. Pharmacokinetic (PK) Parameters: AUCt

    AUC from time zero to the time of the last quantifiable concentration (AUC0-t)

    Time frame: up to 100 days post last dose

  3. Pharmacokinetic (PK) Parameters: Cmax

    Maximum observed concentration

    Time frame: up to 100 days post last dose

  4. Pharmacokinetic Parameters: Tmax

    Time of peak concentration (Tmax)

    Time frame: up to 100 days post last dose

  5. Pharmacokinetic Parameters: T1/2

    Investigational Product (IP) half-life (T1/2)

    Time frame: up to 100 days post last dose

07

Study locations

7 of 21 sites recruiting
  • Stern Center for Cancer Clinical Trials and Research
    Orange, California 92868, United States
    Recruiting
  • UCHealth Cancer Care - Anschutz Medical Campus
    Aurora, Colorado 80045, United States
    Recruiting
  • Horizon Oncology Research, LLC.
    Layfayette, Indiana 47905, United States
    Completed

    Not enrolling at this site — choose another above.

  • Mass General Hospital
    Boston, Massachusetts 02114, United States
    Recruiting
  • Rutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey 08901, United States
    Completed

    Not enrolling at this site — choose another above.

  • NYU Langone
    New York, New York 10016, United States
    Recruiting
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
  • Carolina BioOncology Institute
    Huntersville, North Carolina 28078, United States
    Completed

    Not enrolling at this site — choose another above.

  • Vanderbilt-Ingram Cancer Center
    Nashville, Tennessee 37232, United States
    Completed

    Not enrolling at this site — choose another above.

  • Mary Crowley Cancer Research
    Dallas, Texas 75230, United States
    Completed

    Not enrolling at this site — choose another above.

  • UW Carbone Cancer Center
    Madison, Wisconsin 53705, United States
    Recruiting
  • The Second Hospital of Anhui Medical University
    Hefei, Anhui 230601, China
    Withdrawn

    Not enrolling at this site — choose another above.

  • Beijing Cancer Hospital
    Beijing, Beijing Municipality 100142, China
    Recruiting
  • Sixth Affiliated Hospital, Sun Yat-sen University
    Guangzhou, Guangdong 510655, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • HARBIN Medical University Cancer Hospital
    Harbin, Heilongjiang 150086, China
    Completed

    Not enrolling at this site — choose another above.

  • Henan Cancer Hospital
    Zhengzhou, Henan 45003, China
    Completed

    Not enrolling at this site — choose another above.

  • Hubei Cancer Hospital
    Wuhan, Hubei 430079, China
    Completed

    Not enrolling at this site — choose another above.

  • The First Hospital of China Medical University
    Shenyang, Liaoning 110499, China
    Completed

    Not enrolling at this site — choose another above.

  • Zhongshan Hospital, Fudan University
    Shanghai, Shanghai Municipality 200032, China
    Completed

    Not enrolling at this site — choose another above.

  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin Municipality 300060, China
    Completed

    Not enrolling at this site — choose another above.

  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 3110020, China
    Completed

    Not enrolling at this site — choose another above.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2021 (actual). Primary completion is estimated for Dec 2026, 66 months after the start.

Of 287 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's planned 66 months is above that.

Counting every sponsor, half of 497 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2021
First posted
May 25, 2021
StartActual
Jun 29, 2021
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04900818
Lead sponsor
I-Mab Biopharma US Limited
Responsible party
Sponsor
First posted
May 25, 2021
Start date
Jun 29, 2021
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Mar 5, 2026

Study contacts

Clinical Development
Contact
us.info@imabbio.com
(240) 745-6330

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion